Wave (WVE) Reports Q2 2025 Earnings with Revenue Decline and Increased Expenses
Wave (WVE) reported Q2 2025 earnings with revenue declining to $8.7 million from $19.7 million, attributed to timing of revenue recognition under the GSK collaboration. The company also saw increased R&D and general and administrative expenses, leading to a net loss of $50.5 million. Despite the financial challenges, the company maintains sufficient cash reserves to fund operations through 2027.
Topics: clinical data expenses financial results net loss revenue